COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01032148
Recruitment Status : Terminated (lack of funding)
First Posted : December 15, 2009
Last Update Posted : January 12, 2017
Information provided by (Responsible Party):
Roswell Park Cancer Institute

Brief Summary:
The purpose of this study is to find out the effects of a drug called LBH589 when given to people with recurrent or refractory Hodgkin or Non-Hodgkin's lymphoma. The safety of this drug will also be studied. The participants' physical state, changes in the size of the tumor, or state of Hodgkin or non-Hodgkin's Lymphoma, and laboratory findings taken while on-study will help the researchers decide if LBH589 is safe and effective.

Condition or disease Intervention/treatment Phase
Hodgkin's Lymphoma Non-Hodgkin's Lymphoma Drug: LBH589 Phase 1

Detailed Description:
This is an open-label, standard 3-3 dose finding scheme with a modification that allows intra-patient dose modification to determine maximum tolerated dose and toxicity profile of LBH589 in patients with recurrent or refractory Hodgkin's or non-Hodgkin's lymphoma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of LBH589, A Novel Oral Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Study Start Date : December 2009
Actual Primary Completion Date : January 2017
Actual Study Completion Date : January 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: LBH589
LBH589 administered orally as once daily dose of 20 mg po q M, W, F on a q 28 day cycle, escalating to a maximum dase of 60 mg
Drug: LBH589
LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.

Primary Outcome Measures :
  1. Determine maximum tolerated dose (MTD) of LBH589 [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Determine toxicity profile in study population [ Time Frame: 28 days after Cycle 2 Day 1 ]
  2. Determine anti-lymphoma activity of LBH589 in (non-CTCL) Hodgkin's and non-Hodgkin's lymphoma patients [ Time Frame: 2 Years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients age ≥ 18 years old with relapsed/refractory Hodgkin lymphoma or NHL patients who have relapsed or are refractory after receiving a minimum of two prior therapies
  • Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed

Laboratory requirements:

  • ANC ≥ 1.5 x 10(9th)/L, unless due to bone marrow involvement with lymphoma
  • Hemoglobin ≥ 9 g/dl without packed red blood cell dependency, unless due to bone marrow involvement with lymphoma
  • Platelets ≥ 100 x 10(9th)/L, unless due to bone marrow involvement with lymphoma
  • Serum creatinine ≤ 1.5 x Upper limit of Normal, or calculated Creatinine Clearance ≥ 50 mL/min
  • AST and ALT ≤ 2.5 x Upper limit of Normal, unless due to liver involvement with lymphoma
  • Serum bilirubin ≤ 1.5 x Upper limit of Normal
  • Albumin > 3.0 g/dl
  • Serum potassium ≥ Lower limit of Normal
  • Total serum calcium [corrected for serum albumin] or ionized calcium ≥ Lower limits of normal
  • Serum magnesium ≥ Lower limit of Normal
  • Serum phosphorus ≥ Lower limit of Normal
  • TSH ≥ LLN and free T4 within normal limits. Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism.
  • Baseline MUGA or ECHO must demonstrate LVEF ≥ 50%
  • ECOG Performance Status of ≤ 2

Exclusion Criteria:

  • Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer
  • Patients who will need valproic acid for any medication during the study or within 5 days prior to first LBH589 treatment
  • Peripheral neuropathy ≥ CTCAE grade 1
  • Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:
  • Patients with congenital QT syndrome
  • History or presence of sustained ventricular tachyarrhythmia.
  • Any history of ventricular fibrillation or torsade de pointes
  • Bradycardia defined as Heart Rate < 50 bpm. Patients with pacemakers are eligible if Heart Rate ≥ 50 bpm
  • Screening EKG with a QTc.450msec
  • Right Bundle branch block + left anterior hemiblock (bifascicular block)
  • Patients with myocardial infarction or unstable angina ≤ 6 months prior to starting study drug
  • other clinically significant heart disease (e.g. CHF NY Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension or history of poor compliance with an antihypertensive regimen)
  • Impairment of GI function or GI disease that may significantly alter the absorption of LBH589
  • Patients with Diarrhea > CTCAE grade 1
  • Other concurrent severe and/or uncontrolled medical conditions (e.g. uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values that could cause unaccepted safety risks or compromise compliance with the protocol
  • Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug
  • Concomitant use of CYP3A4 inhibitors
  • Patients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites(which ever is longer) and who have not recovered from side effects of those therapies
  • Patients who have received either immunotherapy within ≤ 8 weeks;chemotherapy within ≤ 4 weeks or radiation therapy to >30% of marrow-bearing bone within ≤ weeks prior to starting study treatment or who have not yet recovered from side effects of such therapies
  • Patients with an active bleeding tendency or is receiving any treatment with therapeutic doses of sodium warfarin or coumadin derivatives. Low doses of Coumadin (e.g.≤2 mg/day) to maintain line patency is allowed.
  • Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  • Women who are pregnant or breast feeding or women of childbearing potential not using effective method of birth control
  • Male patients whose sexual partners are women of childbearing potential not using effective birth control
  • Patients with prior malignancy within 5 years (except for basal or squamous cell carcinoma, in situ cancer of the cervix or early stage prostate or bladder carcinomas)
  • Patients with known positivity for HIV or hepatitis C: baseline testing for HIV and Hepatitis C is not required
  • Prior allogenic stem cell transplant
  • Patients with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff
  • Patients taking CYP2D6 inhibitors should be carefully monitored, but these drugs are not necessarily contraindicated when use concomitantly with LBH. Use of these drugs is not an exclusion criterion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01032148

Layout table for location information
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Sponsors and Collaborators
Roswell Park Cancer Institute
Layout table for investigator information
Principal Investigator: Francisco Hernandez, MD Roswell Park Cancer Institute
Layout table for additonal information
Responsible Party: Roswell Park Cancer Institute Identifier: NCT01032148    
Other Study ID Numbers: RPCI I 147408
First Posted: December 15, 2009    Key Record Dates
Last Update Posted: January 12, 2017
Last Verified: January 2017
Keywords provided by Roswell Park Cancer Institute:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action